<- Go Home
Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Market Cap
$36.1B
Volume
31.5M
Cash and Equivalents
$1.1B
EBITDA
$3.5B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$9.0B
Profit Margin
58.44%
52 Week High
$21.84
52 Week Low
$14.02
Dividend
4.47%
Price / Book Value
3.42
Price / Earnings
22.12
Price / Tangible Book Value
-5.07
Enterprise Value
$43.6B
Enterprise Value / EBITDA
12.35
Operating Income
$3.0B
Return on Equity
15.58%
Return on Assets
6.99
Cash and Short Term Investments
$1.1B
Debt
$8.6B
Equity
$10.6B
Revenue
$15.4B
Unlevered FCF
$2.2B
Sector
Personal Care Products
Category
N/A